These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 23796582)

  • 21. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
    Poxton IR
    Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany.
    Watt M; McCrea C; Johal S; Posnett J; Nazir J
    Infection; 2016 Oct; 44(5):599-606. PubMed ID: 27062378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A real-world evaluation of oral vancomycin for severe Clostridium difficile infection: implications for antibiotic stewardship programs.
    Le F; Arora V; Shah DN; Salazar M; Palmer HR; Garey KW
    Pharmacotherapy; 2012 Feb; 32(2):129-34. PubMed ID: 22392421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An antimicrobial stewardship program's real-world experience with fidaxomicin for treatment of Clostridium difficile infection: a case series.
    Vargo CA; Bauer KA; Mangino JE; Johnston JE; Goff DA
    Pharmacotherapy; 2014 Sep; 34(9):901-9. PubMed ID: 24898525
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
    Lam SW; Bass SN; Neuner EA; Bauer SR
    Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk estimation for recurrent Clostridium difficile infection based on clinical factors.
    D'Agostino RB; Collins SH; Pencina KM; Kean Y; Gorbach S
    Clin Infect Dis; 2014 May; 58(10):1386-93. PubMed ID: 24599770
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.
    Pichenot M; Héquette-Ruz R; Le Guern R; Grandbastien B; Charlet C; Wallet F; Schiettecatte S; Loeuillet F; Guery B; Galperine T
    Infection; 2017 Aug; 45(4):425-431. PubMed ID: 28120176
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
    Guery B; Menichetti F; Anttila VJ; Adomakoh N; Aguado JM; Bisnauthsing K; Georgopali A; Goldenberg SD; Karas A; Kazeem G; Longshaw C; Palacios-Fabrega JA; Cornely OA; Vehreschild MJGT;
    Lancet Infect Dis; 2018 Mar; 18(3):296-307. PubMed ID: 29273269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
    Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
    Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection.
    Brandt LJ; Aroniadis OC; Mellow M; Kanatzar A; Kelly C; Park T; Stollman N; Rohlke F; Surawicz C
    Am J Gastroenterol; 2012 Jul; 107(7):1079-87. PubMed ID: 22450732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study.
    Musher DM; Logan N; Bressler AM; Johnson DP; Rossignol JF
    Clin Infect Dis; 2009 Feb; 48(4):e41-6. PubMed ID: 19133801
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tigecycline for the treatment of severe Clostridium difficile infection.
    Larson KC; Belliveau PP; Spooner LM
    Ann Pharmacother; 2011 Jul; 45(7-8):1005-10. PubMed ID: 21730279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of fidaxomicin for the treatment of Clostridium difficile infection.
    Juang P; Hardesty JS
    J Pharm Pract; 2013 Oct; 26(5):491-7. PubMed ID: 24064437
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin: in Clostridium difficile infection.
    Duggan ST
    Drugs; 2011 Dec; 71(18):2445-56. PubMed ID: 22141387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?
    Green MR; Acharya UH; Yeager AM
    J Clin Oncol; 2013 Dec; 31(34):4376-8. PubMed ID: 24166524
    [No Abstract]   [Full Text] [Related]  

  • 37. Fidaxomicin: a new option for the treatment of Clostridium difficile infection.
    Johnson AP; Wilcox MH
    J Antimicrob Chemother; 2012 Dec; 67(12):2788-92. PubMed ID: 22865382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of association of outcomes with treatment duration and microbiologic susceptibility data in Clostridium difficile infections in a non-NAP1/BI/027 setting.
    Venugopal AA; Riederer K; Patel SM; Szpunar S; Jahamy H; Valenti S; Shemes SP; Khatib R; Johnson LB
    Scand J Infect Dis; 2012 Apr; 44(4):243-9. PubMed ID: 22077148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Risks of Incident and Recurrent Clostridium difficile-Associated Diarrhea in Chronic Kidney Disease and End-Stage Kidney Disease Patients: A Systematic Review and Meta-Analysis.
    Phatharacharukul P; Thongprayoon C; Cheungpasitporn W; Edmonds PJ; Mahaparn P; Bruminhent J
    Dig Dis Sci; 2015 Oct; 60(10):2913-22. PubMed ID: 25986528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.
    Goldstein EJ; Citron DM; Sears P; Babakhani F; Sambol SP; Gerding DN
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5194-9. PubMed ID: 21844318
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.